CD40 agonist mitazalimab not checked

Alligator Bioscience AB · ADC-1013 · JNJ-64457107

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.”In the company’s words, NCT04888312 on ClinicalTrials.gov
Tested for
Metastatic Pancreatic Ductal Adenocarcinoma
Main trialPhase 1/2
“Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.”In the company’s words, NCT04888312 on ClinicalTrials.gov
Other names
ADC-1013 · JNJ-64457107

Other drugs for Metastatic Pancreatic Ductal Adenocarcinoma

All 203 drugs for Metastatic Pancreatic Ductal Adenocarcinoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 1 Jun 2026 Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CD40 agonist mitazalimab

Following is part of Solo: you see every change to CD40 agonist mitazalimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in